Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis

T. Koudriavtseva, C. Pozzilli, M. Fiorelli, C. Gasperini, F. Bagnato, S. Galgani, M. Frontoni, O. Ciccarelli, S. Bastianello

Research output: Contribution to journalArticlepeer-review


The decision to use interferon beta (IFN-β) as a treatment for relapsing-remitting multiple sclerosis (RRMS) is based on both clinical characteristics and course of the disease. To better identify the profile of responders, the relationships between baseline clinical/MRI characteristics and therapeutical response was analyzed in 49 patients with RRMS randomly assigned to receive subcutaneously 3 or 9 MIU of IFN-β-1a. The therapeutical response was evaluated as a per cent change in the mean number and volume of monthly Gd-enhancing lesions in both first (early response) and second (late response) 6-month period of treatment compared to the 6-month pre-treatment period. A better early response was seen in patients with a lower number of relapses during the pre-treatment period while the late response was favourably influenced by a lower baseline EDSS and the high dose. Our findings suggest that the effect of IFN-βB-1a on disease MRI activity is dose-related and dependent on the relapse rate and the level of disability before treatment.

Original languageEnglish
Pages (from-to)403-407
Number of pages5
JournalMultiple Sclerosis Journal
Issue number5
Publication statusPublished - Oct 1998


  • Gd-enhanced MRI
  • IFN-β-1a
  • Relapsing-remitting multiple
  • Therapeutical response

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this